Application No.: 10/701,007

Office Action Dated: March 26, 2007

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-3. (canceled)

4. (previously presented) The composition of claim 34 wherein each of the 2'-substituent groups of each Q or each Z is -F, -O-CH₂CH₂-O-CH₃, -O-C₁-C₁₂ alkyl, -O-CH₂-CH₂-CH₂-NH₂, -O-(CH₂)₂-O-N(R₁)₂, -O-CH₂C(=O)-N(R₁)₂, -O-(CH₂)₂-O-(CH₂)₂-N(R₁)₂, -O-CH₂-CH₂-CH₂-NHR₁, -N₃, -O-CH₂-CH=CH₂, -NHCOR₁, -NH₂, -NHR₁, -N(R₁)₂, -SH, -SR₁, -N(H)OH, -N(H)OR₁, -N(R₁)OH, -N(R₁)OR₁ or -O-CH₂-N(H)-C(=NR₁)[N(R₁)₂]; and

wherein each R_1 is, independently, H, a protecting group or substituted or unsubstituted C_1 - C_{12} alkyl, C_2 - C_{12} alkenyl, or C_2 - C_{12} alkynyl wherein the substituent groups are selected from halogen, hydroxyl, amino, azido, cyano, haloalkyl, alkenyl, alkoxy, thioalkoxy, haloalkoxy or aryl.

5. (previously presented) The composition of claim 34 wherein each of the 2'-substituent groups of each Q or each Z is -F, -O-CH₃, -O-CH₂CH₂-O-CH₃, -O-CH₂-CH=CH₂, N₃, NH₂, NHOH, -O-(CH₂)₂-O-N(R₁)₂, -O-CH₂C(O)-N(R₁)₂, -O-CH₂-CH₂-CH₂-NH₂, -O-(CH₂)₂-O-(CH₂)₂-N(R₁)₂ or -O-CH₂-N(H)-C(=NR₁)[N(R₁)₂]; and

wherein each R_1 is, independently, H, a protecting group or substituted or unsubstituted C_1 - C_{12} alkyl, C_2 - C_{12} alkenyl, or C_2 - C_{12} alkynyl wherein the substituent groups are selected from halogen, hydroxyl, amino, azido, cyano, haloalkyl, alkenyl, alkoxy, thioalkoxy, haloalkoxy or aryl.

- 6. (previously presented) The composition of claim 34 wherein each of the 2'-substituent groups of each Q or each Z is -F, -O-CH₂CH₂-O-CH₃, -O-CH₃, -O-CH₂-CH=CH₂ or -O-CH₂-CH-CH₂-NH(R_j) where R_j is H or C₁-C₁₀ alkyl.
- 7. (previously presented) The composition of claim 34 wherein each of the 2'-substituent groups of each Q or each Z is -F, -O-CH₃ or -O-CH₂CH₂-O-CH₃.

Application No.: 10/701,007

Office Action Dated: March 26, 2007

8-33. (canceled)

34. (currently amended) A composition comprising first and second chemically

synthesized oligomeric compounds, wherein:

at least a portion of said first oligomeric compound is capable of hybridizing with at

least a portion of said second oligomeric compound;

at least a portion of said first oligomeric compound is complementary to and capable

of hybridizing to a selected nucleic acid target;

at least one of said first and second oligomeric compounds comprises a contiguous sequence of linked nucleosides wherein the sequence defines an alternating motif having the

formula:

$$5'-Q(-L-Z-L-Q)_n(-L-Z)_{nn}-3'$$

wherein:

each L is an internucleoside linking group;

each Q or each Z is, independently, a nucleoside having a 2' substituent group

that is other than H or OH;

the other of each Q or each Z is a B D deoxyribonucleoside;

each Q is a nucleoside having a 2'-substituent group that is other than H or OH

and each Z is a β-D-deoxyribonucleoside; or

each Q is β-D-deoxyribonucleoside and each Z is a nucleoside having a 2'-

substituent group that is other than H or OH;

n is from about 8 to about 14 and nn is 0 or 1; and

each of said oligomeric compounds is from about 18 to about 30 linked nucleosides in

length.

35-36. (canceled)

37. (previously presented) The composition of claim 34 wherein only one of said first and

said second oligomeric compounds comprises said alternating motif.

Application No.: 10/701,007

Office Action Dated: March 26, 2007

38. (previously presented) The composition of claim 37 wherein both of said first and said

second oligomeric compounds independently comprise said alternating motif.

39-45. (canceled)

46. (previously presented) The oligomeric compound of claim 34 wherein each of the 2'-

substituent groups of each Q or each Z is -F or -O-CH₃.

47-48 (canceled)

49. (previously presented) The composition of claim 34 wherein each Z is a β -D-

deoxyribonucleoside.

50. (previously presented) The composition of claim 34 wherein each Q is a 2'-fluoro

nucleoside.

51. (previously presented) The composition of claim 34 wherein each Q is a 2'-O-CH₃

nucleoside.

52. (canceled)

53. (original) The composition of claim 34 wherein said first oligomeric compound

further comprises a 5'-phosphate group.

54. (original) The composition of claim 34 wherein said second oligomeric

compound further comprises a 5'-phosphate group.

55. (original) The composition of claim 34 wherein each of said first and said second

oligomeric compounds independently, comprise a 5'-phosphate group.

Application No.: 10/701,007

Office Action Dated: March 26, 2007

56. (original) The composition of claim 34 wherein said first oligomeric compound

comprises a 3'-terminal OH group.

57. (original) The composition of claim 34 wherein the nucleosides of each of said

first and said second oligomeric compounds are linked by phosphodiester internucleoside

linking groups.

58. (original) The composition of claim 34 wherein the nucleosides of each of said

first and said second oligomeric compounds are linked by phosphorothioate internucleoside

linking groups.

59. (original) The composition of claim 34 wherein the nucleosides of one said first

and said second oligomeric compound are linked by phosphorothioate internucleoside linking

groups and the nucleosides of the other of said first and said second oligomeric compound are

linked by phosphodiester internucleoside linking groups.

60. (original) The composition of claim 34 wherein the nucleosides of said first

oligomeric compound are linked by phosphorothioate internucleoside linking groups and the

nucleosides of said second oligomeric compound are linked by phosphodiester

internucleoside linking groups.

61. (original) The composition of claim 34 wherein each of the nucleosides of said

first and said second oligomeric compound are independently linked by phosphorothioate or

phosphodiester internucleoside linking groups.

62. (original) The composition of claim 34 wherein each of the nucleosides of said

first and said second oligomeric compound are independently linked by an internucleoside

linking group selected from the group consisting of phosphodiester, phosphorothioate, chiral

phosphorothioate, phosphorodithioate, phosphotriester, aminoalkylphosphotriester, methyl

phosphonate, alkyl phosphonate, 5'-alkylene phosphonate, chiral phosphonate, phosphinate,

phosphoramidate, 3'-amino phosphoramidate, aminoalkylphosphoramidate,

Page 5 of 11

Application No.: 10/701,007

Office Action Dated: March 26, 2007

thionophosphoramidate, thionoalkylphosphonate, thionoalkylphosphotriester, selenophosphate and boranophosphate.

63. (previously presented) The composition of claim 34 wherein each of said first and said

second oligomeric compounds comprise said alternating motif.

64. (canceled)

65. (previously presented) The composition of claim 63 wherein the 2'-substituent group

of each Q is 2'-F or 2'-O-CH₃.

66-71. (canceled)

72. (original) The composition of claim 34 further comprising at least one conjugate

group.

73. (canceled)

74. (original) The composition of claim 34 wherein at least one of said first and said

second oligomeric compounds further comprises at least one terminal cap moiety attached at

the 3'-end, the 5'-end or both the 3'-end and the 5'-end.

75. (original) The composition of claim 74 wherein said terminal cap moiety is an

inverted deoxy abasic moiety.

76. (original) The composition of claim 74 wherein one of said first and second

oligomeric compounds is a sense strand and wherein said sense strand comprises a terminal

cap moiety at one or both of the 3'-terminal and the 5'-terminal ends.

77. (original) The composition of claim 76 wherein said terminal cap moiety is an

inverted deoxy abasic moiety.

Application No.: 10/701,007

Office Action Dated: March 26, 2007

78. (original) The composition of claim 34 wherein said first and said second

oligomeric compounds are a complementary pair of siRNA oligonucleotides.

79-93. (canceled)

94. (previously presented) The composition of claim 34 wherein each of said first and

second oligomeric compounds has from about 21 to about 24 nucleosides.

95. (original) The composition of claim 34 wherein said first oligomeric compound

is an antisense oligonucleotide.

96. (original) The composition of claim 34 wherein said second oligomeric

compound is a sense oligonucleotide.

97-103. (canceled)

104. (previously presented) The composition of claim 34 further comprising one or more

overhangs.

105. (new) The composition of claim 34 wherein said first oligomeric compound

is complementary to and capable of hybridizing with said second oligomeric compound.